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Background: Hemodialysis (HD) is a life-saving treatment for patients with end
stage renal disease. However, HD patients have markedly increased rates of
cardiovascular morbidity and mortality. Previously, a link between the complement
system and cardiovascular events (CV-events) has been reported. In HD, systemic
complement activation occurs due to blood-to-membrane interaction. We hypothesize
that HD-induced complement activation together with inflammation and thrombosis are
involved in the development of CV-events in these patients.
Methods: HD patients were followed for the occurrence of CV-events during amaximum
follow-up of 45 months. Plasma samples were collected from 55 patients at different
time points during one HD session prior to follow-up. Plasma levels of mannose-binding
lectin, properdin and C3d/C3 ratios were assessed by ELISA. In addition, levels of von
Willebrand factor, TNF-α and IL-6/IL-10 ratios were determined. An ex-vivomodel of HD
was used to assess the effect of complement inhibition.
Results: During median follow-up of 32 months, 17 participants developed CV-events.
In the CV-event group, the C3d/C3-ratio sharply increased 30min after the start of the
HD session, while in the event-free group the ratio did not increase. In accordance, HD
patients that developed a CV-event also had a sustained higher IL-6/IL-10-ratio during
the first 60min of the HD session, followed by a greater rise in TNF-α levels and von
Willebrand factor at the end of the session. In the ex-vivo HD model, we found that
complement activation contributed to the induction of TNF-α levels, IL-6/IL-10-ratio and
levels of von Willebrand factor.
Conclusions: In conclusion, these findings suggest that early intradialytic complement
activation predominantly occurred in HD patients who develop a CV-event during
follow-up. In addition, in these patients complement activation was accompanied
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by a pro-inflammatory and pro-thrombotic response. Experimental complement inhibition
revealed that this reaction is secondary to complement activation. Therefore, our data
suggests that HD-induced complement, inflammation and coagulation are involved in
the increased CV risk of HD patients.
Keywords: complement, kidney, cardiovascular risk, hemodialysis, biocompatibility, innate immunity, C1-inhibitor
INTRODUCTION
Renal replacement therapy (RRT) represents a cornerstone in
the treatment of patients with end stage renal disease (ESRD).
Hemodialysis (HD) remains the most common form of RRT
(1). Despite being lifesaving, HD comes with a risk (2). The life
expectancy and quality of life of patients on dialysis is inferior
to the general population. Overall, HD has been associated with
increased cardiovascular morbidity and mortality (3). Previous
studies have suggested that the innate immune system plays a key
role in the development of cardiovascular disease in HD patients
(4).
The complement system is a major component of innate
immunity and activation of this system induces an inflammatory
response (5). Complement activation can occur via three
pathways: the classical pathway (CP), lectin pathway (LP), and
alternative pathway (AP). Regardless of the trigger, all pathways
lead to the cleavage of C3 resulting in the formation of C3b, the
large fragment and C3a, an anaphylatoxin. Ultimately, C3b is
broken down progressively to iC3b and then to the more stable
fragment C3d. The functions of the complement system were
thought to be limited to opsonization and lysis of pathogens.
However, nowadays this system is known to have numerous
functions and complement has been shown to be involved in the
pathogenesis of various diseases (6).
For decades, HD has been known to activate the complement
system (7). In dialysis, complement activation ismainly caused by
the interaction of blood with the HD membrane (4). Regardless
of the efforts to improve biocompatibility, complement activation
still occurs in HD, even with modern membranes (8–10). It
has been hypothesized that complement activation leads to HD-
induced inflammation and thereby increases the subsequent
cardiovascular risk (4). In accordance, several studies have
shown an association between complement and cardiovascular
events (CV-event) (8, 11–14). However, the link between
complement activation products and CV-events remains poorly
characterized (15). Only Lines et al. reported an association
in HD patients between soluble C5b-9 and cardiovascular risk
(15). Furthermore, previous experimental studies proposed a link
between HD-induced complement activation, pro-inflammatory
cytokines, and the coagulation system (10, 16).
Abbreviations: AP, Alternative pathway; BSA, Body surface area; C5b-9,
Membrane attack complex; CV-event, Cardiovascular event; ESRD, End stage
renal disease; ELISA, Enzyme-linked immunosorbent assay; HD, Hemodialysis;
IL-6, Interleukin 6; IL-10, Interleukin 10; LP, Lectin pathway; MBL, Mannose-
binding lectin; RRT, Renal replacement therapy; PCI, Percutaneous coronary
intervention; TNF-α, Tumor necrosis factor-α; vWF, Von Willebrand factor
We hypothesize that an unfavorable complement profile is
seen in HD patients who will develop a CV-event. To investigate
the mechanism of increased cardiovascular risk in HD, we
measured complement activation, pro-inflammatory cytokines
and pro-thrombotic factors during one HD session in patients
that developed a CV-event during follow-up and compared this
to patients without a CV-event during follow-up. Furthermore,
we used an ex-vivo model of HD to further elucidate the role
of complement activation as a trigger for inflammation and
coagulation in HD.
MATERIALS AND METHODS
Study Population and Design
A cohort of 55 hemodialysis patients from Dialysis Center
Groningen and the University Medical Center Groningen were
followed for a maximum of 45 months. The original cohort was
composed out of 109 patients; however, due to a lack of samples
only 55 patients could be included for this study. The protocol has
been previously described (2). In short, patients were included if
the duration of HD therapy was longer than 3 months. Patients
with severe heart failure (NYHA class IV) were excluded. Patient
characteristics were extracted from patient records.
Dialysis Settings
Patients were on maintenance HD treatment for three times
a week with a low-flux polysulfone hollow-fiber dialyzer (F8;
Fresenius Care, Bad Homburg, Germany). The hemodialysis
sessions lasted for 4 h. The blood and dialysate flow rates were
250–350 and 500 mL/min, respectively. A constant ultrafiltration
rate was used. Dialysate composition was as follows: acetate,
3.0 mmol/L; bicarbonate, 34 mmol/L; calcium, 1.5 mmol/L;
chloride, 108 mmol/L; glucose, 1.0 g/L; magnesium, 0.5 mmol/L;
potassium, 1.0 or 2.0 mmol/L; sodium, 139 mmol/L The dialysate
temperature was kept on 36.0 or 36.5◦C. Blood samples were
taken just before the start of the dialysis session, and after 30, 60,
180, and 240min.
Definition of Endpoint
The end-point of the study was defined as the time to the first CV-
event. CV-events included cardiac, cerebrovascular, or peripheral
vascular events. Occurrence of a cardiac event was defined as
a ischemic heart disease (unstable angina pectoris, myocardial
infarction, Coronary Artery Bypass Grafting (CABG) and/or
Percutaneous Coronary Intervention (PCI), sudden cardiac
death and congestive heart failure. In order to classify as acute
myocardial infarction, two out of the following three criteria
had to be present: clinical status, elevated heart enzymes, and
EKG changes. Cerebrovascular events were defined as stroke,
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ischemic insult, or newly diagnosed >70% stenosis of the
extracranial carotid artery. Strokes and ischemic insults had
to be verified by CT or MRI. Peripheral vascular disease was
defined as having intermittent claudication with angiographically
or sonographically proven stenosis >50% of the major arteries
of the lower limbs or ulcers caused by atherosclerotic stenosis or
surgery for this disorder. Transplantation was a censoring event
and the transplantation date was considered as the final follow-up
date (17).
Ex-vivo Model of Hemodialysis
An ex-vivomodel of HDwas used as previously described (18). In
brief, a closed circuit was assembled using a pediatric polysulfone
hollow-fiber dialyzer (FX paed; Fresenius Care, Germany) and
blood lines (SN-Set ONLINEplus BVM 5008-R, Fresenius Care,
Germany). The total volume of the circuit was approximately
50mL. Perfusion was achieved using a Masterflex R© peristaltic
pump (Cole-Parmer, USA) and was flow-controlled (TS410
tubing flow module, Transonic systems Inc, USA) to reach
a perfusion flow of approximately 140 to 160 mL/min. The
temperature was kept constant at 37◦C and controlled by an
external heater. Whole blood was taken from healthy volunteers
(n = 3) and anticoagulated with low-molecular weight heparin
(1 U/mL). Initially, the circuit was primed with NaCl 0.9% and
perfused for approximately 20min to remove air bubbles. Prior
to perfusion, the dialysate compartment was filled with NaCl
0.9% and closed. Next, freshly drawn heparinized blood was
added to the circuit, while the same volume of the saline solution
was discarded. The system was perfused with recirculating blood
for 4 h. Samples were collected at the start of the perfusion
and after 30, 60, 120, 180, and 240min. To investigate the
effect of complement inhibition, two consecutive sessions were
performed for each healthy volunteer. During one session, 200
units of C1-inhibitor (Cinryze©, Viropharma, USA) were added
to the blood prior to perfusion, whereas the other session without
C1-inhibitor (C1-INH) served as a control.
Inflammatory Markers and Pro-thrombotic
Factors
In the HD cohort, TNF-α was measured by Quantikine HS
Human Immunoassay (R&D System Inc., USA). Furthemore,
IL-6 and IL-10 were determined using a quantitative sandwich
enzyme immunoassay technique (R&D System Inc., USA).
Lastly, Von Willebrand Factor (vWF) was measured by enzyme-
linked immunosorbent assay (Dakopatts, UK). In the ex-vivo
HD model, TNF-α, IL-6, IL-10, and vWF were measured using
a human magnetic luminex assay (R&D Systems Inc, USA)
according to the manufacturer’s instructions.
Quantification of Complement Proteins
C3d was measured by sandwich enzyme immunoassay as
previously described (19). Quantitative antigenic assay for C3
was performed by the radial immunodiffusion technique with
monospecific anti-sera (19). The C3d/C3 ratio was determined
by dividing the C3d values in µg/mL by the C3 concentration in
mg/mL. Additionally, Properdin and MBL concentrations were
measured as described earlier (19, 20).
Statistics
Statistical analysis was performed using IBM SPSS 22.0 (IBM
Corporation, Chicago, IL, USA). Normally distributed data
are presented as mean ± standard deviation, whereas non-
normally distributed data are shown as median with interquartile
range. Nominal data are displayed as total number of patients
with percentage [n (%)]. Differences between two groups were
assessed with the student t-test, whereas the paired t-test was
used to compare values of a single variable during different time
points within the HD session. A one-way ANOVA was used
when assessing for differences in multiple groups, followed by
Bonferroni’s post-hoc comparisons tests. The association between
different variables and the incidence of CV-event were assessed
by Cox proportional hazard regression. The Harrell’s C statistic is
the equivalent of the area under the ROC curve, if the outcome is
binary (21).
Ethics
This study was performed in accordance to the Declaration of
Helsinki and was approved by the Medical Ethical Committee
from the University Medical Center Groningen. All participants
signed informed written consent.
RESULTS
Patients Characteristics
Blood samples from 55 patients on maintenance HD were
available, of which 35 were male and 20 female (Table 1). The
mean age was 62 ± 15 years and baseline dialysis vintage was
1.2 years [IQR: 0.6–3.9 years]. The median follow-up of the study
was 32 months and during this time 17 patients (31%) developed
a CV-event, whereas 16 patients died (29%). In our study, the
causes of death were cardiovascular (44%), infection (12.5%),
discontinuation of the HD treatment (12.5%), or unknown
(31%). Among the patients that developed CV-events, 35% had
acute coronary syndrome, 17% needed coronary artery bypass
surgery, 11% developed congestive heart failure, 17% had a
cerebro-vascular accident and 17% developed peripheral vascular
disease. Next, we created two different groups; the 17 patients that
developed a CV-event during follow-up (CV-event group) and
the 38 patients that remained event-free (event-free group).
Complement Activation in the HD Patients
To assess complement activation, we determined the C3d/C3-
ratio in 55 patients during one HD session at the start of the
follow-up. The C3d/C3-ratio at baseline was not statistically
different between the patients that would develop a CV-event
(7.0 ± 6.2) compared to the patients that would not (9.0 ±
7.4). Surprisingly, at the end of the HD session the C3d/C3-ratio
was also not statistically different between the two groups (CV-
event group: 11.8± 8.5, event-free group: 12.9± 10.0). However,
when the intradialytic C3d/C3-ratios were compared between the
two groups, clear differences were seen (Figure 1 and Table 1).
At 30min intradialysis, there was a significant increase in the
C3d/C3-ratio in the CV-event group compared to the patients
who remained event-free. During these initial 30min, the
C3d/C3-ratio increased by 3.29 fold in the CV-event group and
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TABLE 1 | Baseline characteristics of our study population of hemodialysis patients with and without a cardiovascular event.
Patients Univariable
All (n = 55) CV-event (n = 17) No CV-event (n = 38) P* St. beta P#
C3d/C3 RATIO
0min 5.9 [4.8–9.3] 5.6 [4.7–8.1] 6.1 [4.8–11.5] 0.2 −0.02 0.6
30min 9.8 [7.3–17.0] 12.0 [10–33.5] 8.4 [6.8–13.4] 0.01 0.05 0.002
60min 8.4 [5.4–12.4] 7.8 [4.4–11.9] 8.9 [5.6–16.2] 0.2 −0.04 0.2
120min 8.6 [5.5–14.5] 7.4 [5.2–12.7] 9.1 [5.6–16.4] 0.3 −0.03 0.3
240min 8.4 [5.8–17.9] 8.6 [5.9–20.0] 8.3 [5.8–17.9] 0.8 −0.04 0.8
DEMOGRAPHICS
Age, years 62.7 ± 15.8 66.5 ± 11.4 61.0 ± 17.2 0.2 0.01 0.3
Male gender, n (%) 35 (63) 11 (64) 24 (63) 0.9 −0.22 0.6
Current diabetes, n (%) 10 (18) 5 (29) 5 (13) 0.2 0.51 0.3
Hypertension, n (%) 48 (87) 14 (82) 34 (89) 0.2 −0.99 0.1
Cardiovascular history, n (%) 11 (20) 5 (29) 6 (15) 0.2 0.64 0.2
BSA, m2 1.8 ± 0.3 1.7 ± 0.5 1.9 ± 0.2 0.08 −2.04 0.02
HEMODIALYSIS
Dialysis vintage, months 14.1 [7.3–47.3] 12.2 [8.6–50.4] 16.4 [4.7–47.5] 0.5 0.002 0.8
Ultrafiltration volume, L 2.5 ± 0.7 2.4 ± 0.6 2.5 ± 0.7 0.9 0.00 0.7
Ultrafiltration rate, ml/kg/h 8.1 ± 2.3 7.9 ± 1.8 8.2 ± 2.5 0 7 −0.01 0.8
PRIMARY RENAL DISEASE, n (%)
Hypertension 12 (22) 4 (23) 8 (21) 0.8 0.02 0.9
Diabetes 5 (9) 3 (17) 2 (5) 0.1 0.65 0.3
ADPKD 7 (13) 1 (6) 6 (16) 0.3 −0.96 0.3
FSGS 6 (11) 2 (12) 4 (10) 0.8 0.89 0.2
IgA nephropathy 3 (6) 0 (0) 3 (7) 0.2 −3.15 0.4
Chronic pyelonephritis 1 (2) 1 (6) 0 (0) 0.1 2.02 0.06
Glomerulonephrytis 6 (11) 1 (6) 5 (13) 0.4 −0.75 0.4
Other Diagnosis 9 (16) 3 (18) 6 (16) 0.8 0.35 0.6
Unknown 5 (9) 2 (12) 3 (7) 0.8 −0.34 0.9
LABORATORY MEASUREMENTS
Hematocrit, % 34.4 ± 3.7 34.0 ± 4.2 34.6 ± 3.5 0.6 −5.98 0.3
HbA1C, mmol/mol 5.56 ± 0.9 5.7 ± 1.1 5.5 ± 0.8 0.4 0.17 0.4
Albumin, g/L 38 [37-41] 38 [37-41] 38 [36-42] 0.9 0.004 0.9
Calcium, mmol/L 2.32 ± 0.2 2.31 ± 0.1 2.32 ± 0.2 0.8 −0.55 0.6
Phosphate, mmol/L 1.74 ± 0.5 1.70 ± 0.4 1.75 ± 0.6 0.7 0.009 0.9
hsCRP, mg/L 5.5 [1.5–8.8] 5.0 [2.3–11.8] 5.8 [1.4–8.8] 0.5 0.01 0.3
MEDICATION
Aspirin, n (%) 34 (62) 8 (47) 26 (68) 0.2 −0.80 0.09
Calcium channel blockers, n (%) 12 (22) 4 (23) 8 (21) 0.8 −0.14 0.7
β-Blocker, n (%) 31 (56) 10 (59) 21 (55) 0.8 0.24 0.6
ACE inhibitor, n (%) 5 (9) 1 (5) 4 (10) 0.6 −0.44 0.6
AT2–receptor antagonists, n (%) 8 (14) 2 (12) 6 (16) 0.7 −0.41 0.6
Statin, n (%) 13 (24) 2 (12) 11 (29) 0.2 −0.88 0.2
Diuretics, n (%) 5 (9) 2 (12) 3 (7) 0.7 1.11 0.2
P* indicates P-value for the difference in baseline characteristics between the patient with and without a cardiovascular-event. Differences were tested by Student’s t-Test or Mann–
Whitney U test for continuous variables and with χ2 test for categorical variables. Data are presented as mean ± SD or median [IQR]. P# indicates P-value for univariate Cox-regression
for the occurrence of CV-event. Data are presented as beta coefficient with corresponding P-value.
CV, cardiovascular; BSA, body surface area; ADPKPD, autosomal dominant polycystic disease; FSGS, focal segmental glomerulosclerosis; HbA1c, Hemoglobin A1c; hsCRP, high
sensitive C-reactive protein; ACE inhibitor, angiotensin-converting-enzyme inhibitor; AT2-receptor antagonists, Angiotensin II receptor antagonists.
by only 1.26 fold in the event-free group (P < 0.01). In addition,
Cox regression analysis was performed to assess the association
between C3d/C3 ratio at 30min and occurrence of a CV-event
(Table 2). In the crude model, C3d/C3 ratios were associated
with a hazard ratio of 1.06 (95% CI 1.02-1.09; P < 0.001).
After adjustment for age and gender, variables with P < 0.1
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FIGURE 1 | The C3d/C3-ratio during hemodialysis. Course of plasma C3d/C3 ratio in patients that developed a cardiovascular event (CV-event) during follow-up and
in those that remained CV-event free (no CV-event). The data is presented as mean ± SEM and C3d/C3-ratio was calculated by dividing the C3d values (µg/mL) by
the C3 levels (in mg/mL). The C3d/C3-ratio was determined at the start of hemodialysis session and 30, 60, 180 and 240min after. Differences between the two
groups were assessed by the student t-test and a one-way ANOVA followed by Bonferroni’s post-hoc comparisons tests was used to compare C3d/C3 ratios at
different time points within one group (**P < 0.01). The hashtag above the bars denotes a significant difference between the two groups (#P < 0.05), whereas the
asterisk above the bars denotes a significant difference compared to baseline within the group. The number of subject is 17 in the “CV-event group” and 38 in the “No
CV-event group”.
TABLE 2 | Associations of intradialytic complement activation with outcome.
Cardiovascular events
C3d/C3 ratio at 30 min
HR 95% CI P
Model 1 1.06 1.02–1.09 <0.001
Model 2 1.06 1.03–1.09 0.001
Model 3 1.04 1.01–1.08 0.03
Model 4 1.06 1.02–1.09 0.001
Model 5 1.07 1.02–1.09 0.002
Model 1: crude. Model 2: adjusted for age and gender. Model 3: adjusted for BSA, aspirin
and primary chronic pyelonephritis. Model 4: adjusted for DM, cardiovascular history and
hypertension. Model 5: adjusted for HD vintage , UF rate and UF volume.
Data are presented as hazard ratio (HR) plus 95% confidence interval (CI). BSA, body
surface area; DM, diabetes mellitus; HD, Hemodialysis; UF, ultrafiltration rate.
in univariate analysis (BSA, chronic pyelonephritis as primary
renal disease and use of aspirin), cardiovascular risk factors
(CV history, DM and hypertension) or characteristics of HD
(Ultrafiltration rate, ultrafiltration volume and dialysis vintage),
the association between C3d/C3 ratio at 30min and CV-event
remained significant. Subsequently, the Harrell’s-C statistics was
determined to further confirm the potential relationship between
complement activation and CV-events. Plasma C3d/C3 ratio at
30min had a Harrell’s-C statistics of 0.71 (95% CI 0.55–0.88;
P = 0.01).
We next set out to assess the contribution of the AP and LP
to HD-induced complement activation. Due to a lack of samples,
properdin and MBL levels were measured in a subgroup of 30
patients (Figure 2). In this subgroup, there were 11 patients in
the CV-event group and 19 patients in the event free group. MBL
and properdin levels were comparable between the two groups at
the start and at the end of the HD session. Conversely, at 30min
intradialysis, MBL levels decreased significantly in the event-free
group but not in the CV-event group (P < 0.05). Furthermore,
properdin levels were significantly lower at 30min in the CV-
event group, compared to the event-free group. To summarize,
MBL consumption was seen in the event-free group implying
LP activation, while lower properdin levels were observed in the
CV-event group suggesting AP activation.
Inflammatory and Pro-thrombotic Factors
in the HD Patients
We determined cytokines and Von Willebrand factor (vWF)
to investigate if complement activation during HD was
accompanied by a pro-inflammatory response and a pro-
thrombotic state. During HD, distinct time-courses for levels of
vWF were observed between the two groups (Figure 3). In the
CV-event group, vWF levels increased steadily during the session
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FIGURE 2 | Intradialytic levels of properdin and Mannose-binding lectin. Course of plasma mannose-binding lectin (MBL) and properdin in patients that developed a
cardiovascular event (CV-event) during follow-up and in those that remained CV-event free (no CV-event). The data is presented as mean ± SEM. (A) The levels of
MBL were determined at the start of hemodialysis session and 30 and 240min after. (B) The levels of properdin were determined at the start of hemodialysis session
and 30 and 240min after. Differences between the two groups were assessed by the student t-test and a one-way ANOVA followed by Bonferroni’s post-hoc
comparisons tests was used to compare levels at different time points within one group (*P < 0.05). The hashtag above the bars denotes a significant difference
between the two groups (#P < 0.05), whereas the asterisk above the bars denotes a significant difference compared to baseline within the group. The number of
subject is 11 in the “CV-event group” and 19 in the “No CV-event group”.
(P < 0.05). Furthermore, compared to the event-free group, the
CV-event group had significantly higher levels of vWF at 180
and 240min intradialysis (P < 0.05). Cytokines such as tumor
necrosis factor-α (TNF-α) may initiate inflammation and are
therefore believed to play a role in dialysis-related cardiovascular
risk. Levels of TNF-α rose significantly during the HD session in
both groups (Figure 4A). In the CV-event group, levels peaked
at 180min after the start of the HD session (P < 0.01) and
were significantly higher than in the event-free group (P < 0.05).
Furthermore, in the event-free group, the maximum TNF-α
levels were reached at the end of the session (P < 0.001).
To evaluate the relation between anti-inflammatory cytokines
and pro-inflammatory cytokines, we determined the IL-6/IL-
10 ratio (Figure 4B). Interestingly, IL-6/IL-10 ratios were the
highest in both groups at the start of the HD session and
showed a decreasing trend during the dialysis session, although
not significant compared to baseline. Moreover, at 60min
intradialysis an important decrease in the IL-6/IL-10 ratio
occurred in the event-free group, indicating a shift toward a
less inflammatory profile. However, IL-6/IL-10 ratios remained
elevated in the HD patients that developed a CV-event during
follow-up, revealing a significant difference between the groups
at this time point (P < 0.05). Overall, enhanced levels of pro-
inflammatory and pro-thrombotic mediators seem to prelude the
development of CV-events in HD patients.
Ex-vivo Model of Hemodialysis
To further evaluate the effect of HD-induced complement
activation on inflammation and coagulation, we used an ex-vivo
model of HD. During the 4 h of perfusion, the C3d/C3 ratio
increased progressively from 4.7 ± 0.6 at baseline to 55.8 ±
12.5 after 240min (Figure 5A). MBL and properdin levels were
determined to discriminate between complement activation via
the AP and/or the LP. Both MBL and properdin levels decreased
FIGURE 3 | Levels of von Willebrand factor during hemodialysis. Course of
von Willebrand factor (vWF) in patients that developed a cardiovascular event
(CV-event) during follow-up and in those that remained CV-event free (no
CV-event). The data is presented as mean ± SEM. vWF was determined at the
start of hemodialysis session and 60, 180 and 240min after the start of the
session. Differences between the two groups were assessed by the student
t-test and a one-way ANOVA followed by Bonferroni’s post-hoc comparisons
tests was used to compare levels at different time points within one group
(*P < 0.05, **P < 0.01). The hashtag above the bars denotes a significant
difference between the two groups (#P < 0.05), whereas the asterisk above
the bars denotes a significant difference compared to baseline within the
group. The number of subject is 17 in the “CV-event group” and 38 in the “No
CV-event group”.
significantly over time. After 4 h, MBL levels were reduced by
55.2% (P < 0.05) and properdin levels by 34.4%, respectively
(Figure 5). We next assessed inflammatory and pro-thrombotic
factors. Similarly to complement activation, the HD model
resulted in a significant increase in TNF-α, IL-6/IL-10 ratio, and
vWF levels after 240min of dialysis (Figure 6).
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Finally, we evaluated the effect of complement inhibition in
our model to test if complement activation acts as a trigger
for inflammation and coagulation in HD. C1-INH was added
and significantly reduced C3d/C3 ratios compared to controls,
namely from 55.8 ± 13 to 33.1 ± 24 (Figure 5A; P < 0.05). HD-
induced consumption of properdin and MBL was not prevented
by the use of C1-INH.Furthermore, TNF-α levels were 1654
± 631 ng/mL after 240min in the control session, while in
the session with C1-INH levels were reduced to 48.7 ± 74.7
ng/mL(Figure 6A). Correspondingly, a similar trend was seen
after 240min in the IL-6/IL-10 ratio (control session 1086 ± 630
pg/mL, C1-INH session 51± 78 pg/mL; Figure 6C) and for vWF
levels (control session: 98.2 ± 22.7 pg/mL, C1-INH session: 1.7
± 3.3 pg/mL) when the control session was compared to C1-INH
session (Figure 6B). To summarize, C1-INH addition was able to
inhibit HD-induced complement activation and thereby reduce
vWF, TNF-α and IL-6/IL-10 by 98, 97, and 95% respectively.
DISCUSSION
Hemodialysis treatment comes with the balance between the
dangers of advanced uremia and the inherent risks related to
this form of RTT (22, 23). The higher cardiovascular risk seen
in this population is not only related to ESRD but it is also
associated with the HD procedure itself (2). Innate immunity
has been proposed to be the missing link in the mechanism of
CV-events in HD patients (4). We observed distinct differences
in molecular profiles during HD of patients that will later
develop CV-events compared to those who remained event-
free during follow-up. At the start of dialysis, a unique peak in
complement activation was only seen in patients in the CV-event
group. Furthermore, enhanced inflammation and coagulation
accompanied the complement activation seen in HD patient that
will develop CV-events. Moreover, these processes arose long
before the actual development of the CV-event. Altogether these
three elements showed different dynamics, with complement
activation possibly initiating these processes. In accordance,
complement inhibition in our ex-vivo model not only decreased
complement activation but also diminished pro-inflammatory
and pro-thrombotic mediators.
Despite significant advances in the biocompatibility of HD
membranes, complement activation remains an undesired but
relevant issue (8, 15). Higher levels of complement components
as well as loss of complement inhibitors have been associated with
a higher risk for cardiovascular disease in HD patients (8, 11–
14). Recently, complement activation prior to a HD session was
associated with the occurrence of CV-events in HD patients
(15). Here, we showed that activation of C3 during dialysis is
linked to the development of CV-events. Our study is the first,
to our knowledge, to assess the relationship between intradialytic
complement activation and subsequent outcome. In accordance,
previous studies have shown that activation of the complement
system peaks during the first 15 to 30min of the HD session
(24). However, the mechanism by which complement activation
increases the risk for cardiovascular disease remains largely
unknown.
The LP and AP initiate complement activation during HD
(25, 26). In our study, we only found MBL consumption in
the event-free group, implying that this decrease is actually
beneficial. In accordance, MBL has been proposed to be
involved in the removal of atherogenic particles, thereby
decreasing atherosclerosis. Our previous data showed that higher
MBL levels in HD patients were associated with protection
against cardiovascular disease (9). We also found a rise in
properdin levels in the event-free group. Properdin, unlike other
complement factors, is produced by leukocytes, predominately
neutrophils (27). Therefore, the increase in properdin is
presumably the result of leukocyte activation by the HD
membrane leading to degranulation (28). Since, this rise was
not seen in the CV-event group, we speculate this was due to
properdin consumption by AP activation in these patients.
We found higher TNF-α levels and IL-6/IL-10 ratios in
patients that would develop a CV-event. TNF-α and IL-6 are
potent cytokines that can initiate a powerful pro-inflammatory
reaction (29, 30). If this response is not contained, it can lead
to hypotension, organ dysfunction, and eventually result in
death. Elevated levels of these cytokines have also been related
to an increased risk for CV-events in the general population
and in HD patient (31–34). In contrast, IL-10 is a major
anti-inflammatory cytokine with the ability to suppress the
production and secretion of pro-inflammatory mediators in
leukocytes, thereby effectively controlling the inflammation (35).
The IL-6/IL-10 ratio has previously been linked to outcome
after inflammatory disorders and to the development of HD-
induced left ventricular dysfunction (36–38). In ex-vivo models,
the induction of IL-6 during the bio-incompatibility reaction
was shown to be completely complement-dependent, while the
induction of TNF-α was only partially complement-dependent
(16). In addition, in a primate model of HD, complement
inhibition lead to enhanced levels of IL-10, demonstrating the
relationship between the two systems (39).
Thrombosis is a key element in the development of
cardiovascular disease. Previously, Péquériaux et al. reported that
vWF is a good predictor of CV-events in patients undergoing
RRT (40). Von Willebrand factor is a glycoprotein involved in
hemostasis but vWF is also a marker of endothelial cell activation
(41). We found significantly higher levels of vWF in the group of
patients who developed CV-events, which could be evidence of
a prothrombotic state. vWF is produced in endothelial cells and
megakaryocytes, but also stored in the granules of platelets (42).
Considering our ex-vivo lacks endothelial cells, the vWF is most
likely derived from platelets. The release of vWF could either be
the direct effect of complement activation or via C5a-activated
leukocytes (43, 44). The link between the complement system
and thrombosis is not new in HD (45). Complement receptors
on leukocytes are important for the formation of platelet-
leukocytes complexes, which contributes to thrombotic processes
(46). In addition, complement activation during HD induces the
production of pro-coagulation factors (47). Moreover, plasma
levels of C3 correlated with a denser clot structure in HD patients
(48).
The complement system is a strong mediator of the
bioincompatibility reaction. Therefore, we proposed that
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FIGURE 4 | Levels of tumor necrose factor alpha and the ratio of interleukin-6 to interleukin-10 during hemodialysis. Course of tumor necrose factor alpha (TNF-α)
and ratio of interleukin-6 (IL-6) to interleukin-10 (IL-10) in patients that developed a cardiovascular event (CV-event) during follow-up and in those that remained
CV-event free (no CV-event). The data is presented as mean ± SEM. (A) The levels of TNF-α were determined at the start of hemodialysis session and 60, 180 and
240min after the start of the session. (B) Levels IL-6 and IL-10 were determined at the start of hemodialysis session and 60, 180, and 240min after. The IL-6/IL- 10
ratio was calculated by dividing the IL-6 (in pg/mL) values by the IL-10 levels (in pg/mL). Differences between the two groups were assessed by the student t-test and
a one-way ANOVA followed by Bonferroni’s post-hoc comparisons tests was used to compare levels at different time points within one group. (*P < 0.05, **P < 0.01,
***P < 0.001). The hashtag above the bars denotes a significant difference between the two groups (#P < 0.05), whereas the asterisk above the bars denotes a
significant difference compared to baseline within the group. The number of subject is 17 in the “CV-event group” and 38 in the “No CV-event group”.
FIGURE 5 | Complement levels during ex vivo hemodialysis. Two different sessions were performed with whole blood of three healthy donors; one session with
C1-inhibitor (C1-INH) and one session without, the control session. The data is presented as mean ± SEM. (A) C3d/C3 ratios were measured to determine
complement activation. (B) MBL levels significantly decrease over time during the session. (C) Properdin levels were reduced during the session, although not
significantly. Differences between the two groups were assessed by the student t-test and a one-way ANOVA followed by Bonferroni’s post-hoc comparisons tests
was used to compare levels at different time points within one group (*P < 0.05, **P < 0.01). The hashtag above the bars denotes a significant difference between the
two groups (#P < 0.05), whereas the asterisk above the bars denotes a significant difference compared to baseline within the group.
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FIGURE 6 | Levels of tumor necrose factor alpha, ratio of interleukin-6 to interleukin-10 and vWF during ex vivo hemodialysis. Two different sessions were performed
with whole blood of three healthy donors; one session with C1-inhibitor (C1-INH) and one session without, the control session. The data is presented as mean ±
SEM. (A) TNF-α levels significantly increased in the control session, but not in the session with C1-INH. (B) Correspondingly, vWF showed a significant rise in the
control session, while C1 INH additionlead to significantly lower levels. (C) The IL-6/IL-10 ratio progressively increased over time, although not statistically significant.
Differences between the two groups were assessed by the student t-test and a one-way ANOVA followed by Bonferroni’s post-hoc comparisons tests was used to
compare levels at different time points within one group (*P < 0.05). The hashtag above the bars denotes a significant difference between the two groups
(#P < 0.05), whereas the asterisk above the bars denotes a significant difference compared to baseline within the group.
complement activation has an essential role in orchestrating the
inflammatory response in HD. In accordance with the result
observed in the HD patients; our ex-vivo model demonstrated
that the dialyzer induces complement activation, inflammation
and enhances coagulation. We then wondered if HD-induced
inflammation could be attenuated by complement inhibition.
Addition of C1-INH to the ex-vivo HD model significantly
diminished HD-induced complement activation and also
almost completely abolished the induction of TNF-α levels,
L-6/IL-10 ratios and vWF levels. Similarly, Kourtzelis et al,
also demonstrated in an ex vivo model of HD the induction of
coagulation during 2 h of perfusion. In their study, compstatin
was used to block complement activation at the level of C3
(10). We postulate that HD-induced complement activation
results in the formation of anaphylatoxins, thereby resulting
in the activation of peripheral blood mononuclear cell and
platelets initiating a pro-inflammatory and pro-thrombotic
response. Previously, several reports demonstrated that
bioincompatibility-induced inflammation relies mainly
on complement, whereas granulocyte enzyme release was
predominantly C3-dependent, leukocyte activation and pro-
thrombotic mediators were largely dependent on C5 (16, 46).
Altogether, our results support the hypothesis of the complement
system as a key component in HD-induced inflammation and
coagulation, which subsequently leads to a higher risk for
CV-events.
We are aware that our study has strengths and limitations.
Although the study has a long follow up, the samples were only
collected during a single hemodialysis session. Our study could
have benefited from a second assessment of these parameters
during another dialysis session in the same patients, to assess
reproducibility and increase reliability. Furthermore, while
complement activation was seen in the patients during HD as
well as in our ex-vivo model, clear differences were present.
Moreover, in patients a significant peak of complement activation
was seen during the first 30min of HD. In contrast, in our
ex-vivo model a continuous rise of complement activation was
seen until the end of the session. Obviously these discrepancies
arise due to the differences of in-vivo to ex-vivo. For instance,
in the ex-vivo model blood recirculates without re-entering the
human body, therefore it lacks the interaction with endothelial
cells, liver and other organs. Lastly, the size of our cohort could
be considered small and therefore might impact the statistical
analysis. However, due to the long follow up, we achieved a
relatively high number of CV-events which increases the power
of the study in the comparisons between the CV-event group and
the event free group.
There is a growing body of data supporting a role for
the complement system in the development of cardiovascular
disease. Ekdahl et al. proposed that complement activation
initiates an inflammatory cascade and amplifies pro-thrombotic
processes (4). For the first time, to our knowledge, we
demonstrated intradialytic differences in complement activation,
inflammation and a pro-thrombotic factor in HD patients that
will develop a CV-event compared to HD patients that will not.
Furthermore, we showed that complement inhibition during HD
resulted in decreased levels of the pro-inflammatory and pro-
thrombotic mediators. Future studies have to determine what the
ideal target is to inhibit complement in HD to attenuate these
processes and to determine if this decreases the risk of CV-events
in HD patients.
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